COEP Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -1221.06% compared to Coeptis Therapeutics Holdings, Inc.'s net margin of --. Coeptis Therapeutics Holdings, Inc.'s return on equity of -166.72% beat CEL-SCI Corp.'s return on equity of -266.61%.

Coeptis Therapeutics Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 309.28%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that CEL-SCI Corp. has higher upside potential than Coeptis Therapeutics Holdings, Inc., analysts believe CEL-SCI Corp. is more attractive than Coeptis Therapeutics Holdings, Inc..

Coeptis Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Coeptis Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coeptis Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Coeptis Therapeutics Holdings, Inc. quarterly revenues are $237.4K, which are larger than CEL-SCI Corp. quarterly revenues of --. Coeptis Therapeutics Holdings, Inc.'s net income of -$2.9M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Coeptis Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coeptis Therapeutics Holdings, Inc. is 99.79x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -1221.06% compared to Coeptis Therapeutics Holdings, Inc.'s net margin of -953.4%. Coeptis Therapeutics Holdings, Inc.'s return on equity of -166.72% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Coeptis Therapeutics Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 309.28%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that IGC Pharma, Inc. has higher upside potential than Coeptis Therapeutics Holdings, Inc., analysts believe IGC Pharma, Inc. is more attractive than Coeptis Therapeutics Holdings, Inc..

Coeptis Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Coeptis Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coeptis Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Coeptis Therapeutics Holdings, Inc. quarterly revenues are $237.4K, which are larger than IGC Pharma, Inc. quarterly revenues of $191K. Coeptis Therapeutics Holdings, Inc.'s net income of -$2.9M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Coeptis Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coeptis Therapeutics Holdings, Inc. is 99.79x versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -1221.06% compared to Coeptis Therapeutics Holdings, Inc.'s net margin of -255.85%. Coeptis Therapeutics Holdings, Inc.'s return on equity of -166.72% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Coeptis Therapeutics Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 309.28%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that Coeptis Therapeutics Holdings, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Coeptis Therapeutics Holdings, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Coeptis Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Coeptis Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Coeptis Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Coeptis Therapeutics Holdings, Inc. quarterly revenues are $237.4K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Coeptis Therapeutics Holdings, Inc.'s net income of -$2.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Coeptis Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coeptis Therapeutics Holdings, Inc. is 99.79x versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -1221.06% compared to Coeptis Therapeutics Holdings, Inc.'s net margin of 13.19%. Coeptis Therapeutics Holdings, Inc.'s return on equity of -166.72% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Coeptis Therapeutics Holdings, Inc. has a consensus price target of --, signalling upside risk potential of 309.28%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 535.84%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Coeptis Therapeutics Holdings, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Coeptis Therapeutics Holdings, Inc..

Coeptis Therapeutics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Coeptis Therapeutics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Coeptis Therapeutics Holdings, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Coeptis Therapeutics Holdings, Inc. quarterly revenues are $237.4K, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Coeptis Therapeutics Holdings, Inc.'s net income of -$2.9M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Coeptis Therapeutics Holdings, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Coeptis Therapeutics Holdings, Inc. is 99.79x versus 2.20x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.